Canopy Growth Seeks Shareholder Nod for Reverse Split, Advance Notice By-Law, and Incentive Plan Renewal Amid Restatement Fallout
CGC is trading near its 52-week low of $0.844 (13% above the low) on light trading volume (0.2× avg).
Summary
Canopy Growth's proxy seeks approval for a reverse stock split to maintain its Nasdaq listing, alongside an advance notice by-law and incentive plan renewal. The filing discloses a recent management cease trade order, a material weakness in internal controls, and a restatement of prior financials.
Key Events · Corporate Governance and Compliance · CGC
-
Reverse Stock Split Proposed
To lift the stock price above $1.00 and preserve its Nasdaq listing, the board seeks authority to consolidate shares at a ratio between 1-for-5 and 1-for-15. If approved, the exact ratio will be set by the board within 12 months.
-
Management Cease Trade Order Disclosed
On May 28, 2026, the Ontario Securities Commission issued a management cease trade order against CEO Luc Mongeau and CFO Thomas Stewart following a restatement of prior financials. The order was lifted on June 16, 2026, after the restated 10-K was filed.
-
Material Weakness and Restatement Acknowledged
A non-cash accounting error related to warrant classification forced the company to restate its fiscal 2024 and 2025 financials. A material weakness in internal controls was identified, and the company disclosed a default by its major U.S. investment, Acreage Holdings.
-
Advance Notice By-Law and Incentive Plan Renewal
Shareholders will vote on an advance notice by-law for director nominations and the renewal of the Omnibus Incentive Plan. Though standard governance items, they carry added weight given the company's recent control failures.
Analysis · CGC · Life Sciences
Canopy Growth's preliminary proxy paints a picture of a company under severe strain. To stave off a Nasdaq delisting—with shares languishing near $0.95—the board is asking shareholders to authorize a reverse stock split at a ratio between 1-for-5 and 1-for-15. The filing also reveals that a management cease trade order was imposed on the CEO and CFO in May 2026 (lifted the following month), a material weakness exists in internal controls, and two years of financials have been restated. These are serious governance red flags. While the advance notice by-law and incentive plan renewal are routine, the reverse split and the frank admission of recent regulatory and accounting failures signal a company fighting for its listing and its credibility.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1059 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGC was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $417.9M. The 52-week trading range was $0.84 to $2.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.